Cervical cancer is a malignant disease arising from cells of the cervix, most often linked to persistent infection with high-risk human papillomavirus (HPV) types.
ImmunityBio said the Saudi FDA encouraged submission of a regulatory package for recombinant BCG and opened talks on expanding ANKTIVA with checkpoint inhibitors to additional tumor types. The company expects to file the rBCG package within weeks.
A novel therapeutic vaccine using structural nanomedicine principles has shown promising results against HPV-driven cancers in preclinical models. The spherical nucleic acid vaccine design significantly slowed tumor growth and extended survival by generating potent T-cell responses. Unlike preventive HPV vaccines, this approach is designed to treat established cancers caused by the virus.
DelveInsight pipeline reports reveal robust clinical development across three cancer indications, with 45+ companies advancing cutaneous squamous cell carcinoma therapies, 70+ companies developing liver cancer treatments, and multiple hepatocellular carcinoma candidates receiving FDA designations in 2025-2026.
ImmunityBio resubmitted its supplemental BLA to the FDA for ANKTIVA in papillary bladder cancer after providing additional data. The company also received encouragement from Saudi regulators to submit a recombinant BCG application and expand ANKTIVA approvals.
ImmunityBio received European Commission authorization for ANKTIVA in bladder cancer, expanding to 33 countries. The company held productive discussions with Saudi regulators on recombinant BCG and checkpoint inhibitor combinations.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07594327 |
Quality of Life and Sexuality After Pelvic Exenteration for Gynecologic Cancer |
ENROLLING_BY_INVITATION | |
| NCT07273383 |
Self-sampling for HPV Screening |
ACTIVE_NOT_RECRUITING | NA |
| NCT07130240 |
Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 and IIA1 Cervical Cancer |
RECRUITING | PHASE2 |
| NCT07093593 |
Emergence of Bacterial Resistance to Antibiotics in the Digestive Microbiota of Patients Treated With Anticancer Drugs |
NOT_YET_RECRUITING | NA |
| NCT07038369 |
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT07022470 |
Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT). |
RECRUITING | PHASE2 |
| NCT07003620 |
Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial |
RECRUITING | PHASE2 |
| NCT06999824 |
Revisiting the Concept of Nerve Sparing Radical Hysterectomy |
NOT_YET_RECRUITING | |
| NCT06958068 |
Sexual Health Integration in Treatment of Gynecological Oncology |
COMPLETED | |
| NCT06942286 |
Primary HPV Self-Collection in Indonesia |
ENROLLING_BY_INVITATION | NA |
